We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+2.31%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$720M
AUM Growth
-$214M
Cap. Flow
-$176M
Cap. Flow %
-24.45%
Top 10 Hldgs %
53.82%
Holding
93
New
36
Increased
15
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$16.4M
2
BIIB icon
Biogen
BIIB
+$11.8M
3
ADBE icon
Adobe
ADBE
+$11M
4
PANW icon
Palo Alto Networks
PANW
+$10.9M
5
KRNT icon
Kornit Digital
KRNT
+$9.29M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$32.5M
2
FIVN icon
FIVE9
FIVN
+$12.8M
3
ALT icon
Altimmune
ALT
+$11.7M
4
NICE icon
Nice
NICE
+$10.9M
5
JNJ icon
Johnson & Johnson
JNJ
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 66.02%
2 Technology 7.17%
3 Industrials 1.19%
4 Consumer Discretionary 1.16%
5 Communication Services 1.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMTX icon
26
Immatics
IMTX
$1.18B
$7.95M 1.1%
795,406
+64,694
+9% +$698K
PERI icon
27
Perion Network
PERI
$375M
$7.82M 1.08%
+405,184
New +$8.17M
KROS icon
28
Keros Therapeutics
KROS
$199M
$7.78M 1.08%
206,819
+138,822
+204% +$4.81M
ALT icon
29
Altimmune
ALT
$552M
$7.67M 1.06%
600,298
-792,586
-57% -$11.7M
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.45B
$7.19M 1%
+173,696
New +$8.93M
S icon
31
SentinelOne
S
$6.53B
$7.16M 0.99%
+280,000
New +$7.35M
RLMD icon
32
Relmada Therapeutics
RLMD
$557M
$7.15M 0.99%
193,230
-273,600
-59% -$7.58M
ALBO
33
DELISTED
Albireo Pharma Inc
ALBO
$6.95M 0.96%
+359,000
New +$7.42M
SEDG icon
34
SolarEdge
SEDG
$2.51B
$6.81M 0.95%
+29,426
New +$8.68M
GILD icon
35
Gilead Sciences
GILD
$162B
$6.48M 0.9%
+105,090
New +$6.63M
CNCE
36
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.38M 0.89%
952,783
+273,383
+40% +$1.66M
GNRC icon
37
CALL
Generac Holdings
GNRC
$11.6B
$6.34M 0.88%
+35,600
New +$8.16M
MRUS
38
DELISTED
Merus
MRUS
$6.28M 0.87%
313,326
-95,835
-23% -$2.29M
ACLX
39
DELISTED
Arcellx
ACLX
$6.27M 0.87%
+334,080
New +$6.39M
TEVA icon
40
Teva Pharmaceuticals
TEVA
$40.8B
$6.26M 0.87%
776,346
-371,532
-32% -$3.29M
BLU
41
DELISTED
BELLUS Health Inc.
BLU
$4.91M 0.68%
+464,860
New +$4.94M
NVDA icon
42
NVIDIA
NVDA
$4.86T
$4.86M 0.67%
400,000
+287,120
+254% +$4.54M
S icon
43
CALL
SentinelOne
S
$6.53B
$4.21M 0.58%
+164,800
New +$4.33M
CINC
44
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$3.9M 0.54%
+118,950
New +$3.36M
ETNB
45
DELISTED
89bio
ETNB
$3.81M 0.53%
658,784
+208,784
+46% +$917K
RLMD icon
46
PUT
Relmada Therapeutics
RLMD
$557M
$3.44M 0.48%
+93,000
New +$2.58M
RZLT icon
47
Rezolute
RZLT
$454M
$3.17M 0.44%
1,155,897
– –
INZY
48
DELISTED
Inozyme Pharma
INZY
$3.15M 0.44%
1,175,058
+9,458
+0.8% +$34.2K
DICE
49
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$3.1M 0.43%
+152,913
New +$2.79M
DICE
50
PUT
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$3.04M 0.42%
+150,000
New +$2.73M
1
2
3 4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2022 Portfolio in Review

As of Q3 2022, Sphera Funds Management held 93 positions worth $720M, down 23% from $935M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management withdrew a net $176M in Q3 2022, closing 19 positions and reducing 13 holdings. Its most notable exit was State Street SPDR S&P Biotech ETF, an estimated $32.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 47% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Biogen worth $14.8M.

  • Sphera Funds Management's largest Q3 2022 buy was Biogen: 55,500 shares worth $14.8M.
  • Sphera Funds Management added most to Sanofi in Q3 2022, an estimated $16.4M increase.
  • Sphera Funds Management's biggest Q3 2022 reduction was Altimmune, cutting an estimated $11.7M.
  • Sphera Funds Management fully exited State Street SPDR S&P Biotech ETF in Q3 2022, selling an estimated $32.5M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $720M portfolio in Q3 2022.
  • Sphera Funds Management opened 36 new positions and closed 19 in Q3 2022.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $720M.

Based on Sphera Funds Management's 13F filing for Q3 2022, filed 14 Nov 2022.